The natural history of Hepatitis C virus infection: Host, viral, and environmental factors

JAMA

Volumn 284, Issue 4, 2000, Pages 450-456

  Thomas, David L ^a,b   Astemborski, Jacquie ^a   Rai, Rudra M ^a   Anania, Frank A ^a   Schaeffer, Melody ^a   Galai, Noya ^a   Nolt, Karen ^a   Nelson, Kenrad E ^a   Strathdee, Steffanie A ^a   Johnson, Lisette ^a   Laeyendecker, Oliver ^a   Boitnott, John ^a   Wilson, Lucy E ^a   Vlahov, David ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Departments of Pediatrics Medicine Oncology and Radiation Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALCOHOL CONSUMPTION; ARTICLE; DRUG ABUSE; ENVIRONMENTAL FACTOR; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NEGRO; OUTCOMES RESEARCH; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIREMIA;

EID: 0034718227     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. World Health Organization. Weekly Epidemiological Record. Geneva, Switzerland: World Health Organization; 1997:341-348.
2. Alter MJ, Kruszon-Moran D, Hainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341: 556-562.
3. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med. 1992;327:1899-1905.
4. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-914.
5. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991;325:98-104.
6. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting post-transfusion hepatitis C. Hepatology. 1995;21:639-644.
7. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver. 1993;13:274-278.
8. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
9. Seeff LB, Buskell-Bales ZB, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med. 1992;327:1906-1911.
10. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med. 1993;119:110-115.
11. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228-1233.
12. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990; 12:671-675.
13. Hopf U, Moller B, KutherD, et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990; 10:69-76.
14. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology. 1991;14:969-974.
15. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992;16:273-281.
16. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-111.
17. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999; 341:866-870.
18. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis Hepatology. 1998;27:914-919.
19. Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730-1735.
20. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998;27:1717-1722.
21. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA. 1998:279:35-40.
22. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones A, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med. 1981;94:744-748.
23. Mellors JW, Rinaldo CRJ, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
24. Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high titer viremia correlates with advanced stage of disease. J Infect Dis. 1994;169:1219-1225.
25. De Moliner L, Pontisso P, De Salvo GL, Cavallerto L, Chernello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut. 1998;42:856-860.
26. Haydon GH, Jarvis LM, Blair CS, et al. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut. 1998;42:570-575.
27. Negro F, Krawczynski K, Quadri R, et al. Detection of genomic-and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse transcriptase polymerase chain reaction. Hepatology. 1999;29:536-542.
28. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods. J Drug Issues. 1991;21:759-776.
29. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997;35:3274-3277.
30. Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C Lancet. 1993;341:1501-1504.
31. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884-892.
32. Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting drug users: association with drug injection patterns. Am J Epidemiol. 1995; 142:331-341
33. Inglesby TV, Rai R, Astemborski J, et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology. 1999;29:590-596.
34. Knodell RC, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
35. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users in Baltimore. Medicine. 1995;74:212-220.
36. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86: 655-661.
37. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis. 2000;181:844-851.
38. Ohkawa K, Hayashi N, Yuki N, et al. Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol. 1995;46:258-264.
39. Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection. J Infect Dis. 1992;165:831-834.
40. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431.
41. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1993;6:602-610.
42. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-1055.
43. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996; 24:141-147.
44. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394-1402.